Seroepidemiological Study of Toxoplasma gondii Infection among Psychiatric Patients in Mashhad, Northeast of Iran

  • Ebrahim ABDOLLAHIAN Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Reza SHAFIEI Vector-Borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran Dept. of Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Naghmeh MOKHBER Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Kurosh KALANTAR Dept. of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Abdolmajid FATA Dept. of Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Research Center for Skin Diseases and Cutaneous Leishmaniasis, Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords: Toxoplasma gondii, Psychiatric patients, ELISA

Abstract

Background: Psychiatric patients have an increased risk of some infections like toxoplasmosis. Investigations on Toxoplasma gondii infection among psychiatric patients have been limited in Mashhad, Northeast of Iran. In this case-control study, prevalence of T. gondii was investigated by serological method.Methods: This case-control study was performed among psychiatric patients admitted to Avicenna Hospital in Mashhad, Northeast of Iran. Three hundred and fifty inpatients and 350 controls were examined in 2012-2013 for detection of IgG and IgM antibodies against T. gondii in their blood sera by ELISA. Socio-demographic and clinical manifestations of the patients were obtained.Results: Anti-T. gondii IgG antibodies was found in 164 (46.85%) of 350 psychiatric inpatients and 120 (34.28%) of 350 controls. Seventeen (4.85%) of psychiatric individuals and 3 (0.85%) of control group were IgM+/IgG- indicating acute form of toxoplasmosis. There were no statistically significant differences between the case and control groups. In patient group, schizophrenic patients had the highest positive rate (46.28%) and bipolar mood disorder had the second most prevalent rate (20%). Of 162 schizophrenia patients, 65 (40.1%) had latent infection which was higher than that observed in controls.Conclusion: The prevalence of T. gondii infection among psychiatric patients suffering from schizophrenia was more in Mashhad, compared with control group.

References

Alvarado-Esquivel C, Urbina-Alvarez JD, Estrada-Martinez S et al. Toxoplasma gondii infection and schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int. 2011; 60(2): 151-5.

De Hert M, Wampers M, Van Eyck D et al. Prevalence of HIV and hepatitis C infection among patients with schizophrenia. Schizophr Res. 2009; 108(1-3): 307-8.

Nakamura Y, Koh M, Miyoshi E, Ida O, et al. High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(3): 591-7.

Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull. 2006; 32(2): 200-2.

Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006; 114(1): 40-8.

Wastling J, Heap S, Ferguson D. Toxoplasma gondii--keeping our guests under control. Biologist (London). 2000; 47(5): 234-8.

Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000; 30(12-13): 1217-58.

Kravetz JD, Federman DG. Toxoplasmosis in pregnancy. Am J Med. 2005; 118(3): 212-6.

Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363 (9425): 1965-76.

Flegr J. How and why Toxoplasma makes us crazy. Trends Parasitol. 2013; 29(4): 156-63.

Flegr J. Effects of Toxoplasma on human behavior. Schizophr Bull. 2007; 33(3): 757-60.

Hamidinejat H, Ghorbanpoor M, Hosseini H, Alavi SM, Nabavi L, Jalali MH, et al. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis. 2010; 14(11): e978-81.

Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neur-oimmunomodulation. 2009; 16(2): 122-33.

Tamer GS, Dundar D, Yalug I, Caliskan S, Yazar S, Aker A. The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Adv Ther. 2008; 25(7): 703-9.

Alvarado-Esquivel C, Sifuentes-Alvarez A, Narro-Duarte SG et al. Seroepidemiology of Toxoplasma gondii infection in pregnant women in a public hospital in northern Mexico. BMC Infect Dis. 2006; 13;6:113.

Guy E, Dubey JP and Hill DE. Toxoplasma gondii. Smith LJ and Robertson HV, In: Food-borne Protozoan Parasites. Nova Biomedical. 2012: 167-188

Hashemi HJ, Saraei M. Seroprevalence of Toxoplasma gondii in unmarried women in Qazvin, Islamic Republic of Iran. East Mediterr Health J. 2010; 16(1): 24-8.

Salahi-Moghaddam A, Hafizi A. A serological study on Toxoplasma gondii infection among people in south of Tehran, Iran. Korean J Parasitol. 2009; 47(1): 61-3.

Assmar M, Amirkhani A, Piazak N, Hovanesian A, Kooloobandi A, Etessami R. Toxoplasmosis in Iran. Results of a seroepidemiological study. Bull Soc Pathol Exot. 1997; 90(1): 19-21.

First M SR, Gibbon M, Williams J. Structured clinical interview for DSM-IV axis 1 disorders (SCID-1). clinician version American Psychiatric Press. Washington, DC. 1997.

Shafiei R, Riazi R, Sarvghad MR, Galian Sharifdini M, Mahmoodzadeh A, Hajia M. Prevalence of IgG and IgM anti-Toxoplasma gondii antibodies in HIV positive patients in northeast of Iran. Iran J Pathology. 2011; 6(2): 68-72.

Ahmad D, Mehdi S, Sayed HH, Sayed AK, Shirzad G. Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Trop Biomed. 2010; 27(3): 476-82.

Khademvatan S, Khajeddin N, Izadi S, Yousefi E. Investigation of anti-Toxocara and anti-Toxoplasma antibodies in patients with schizophrenia disorder. Schizophr Res Treatment. 2014; 2014: 230349.

Saraei-Sahnesaraei M, Shamloo F, Jahani Hashemi H, Khabbaz F, Alizadeh SA. Relation between Toxoplasma gondii infections and schizophrenia. IJPCP. 2009; 15(1): 3-9.

Fata A, Elahi R, Berenji F, Zarae R, Ghabouli MJ, Ashrafi Abyaneh H. Evaluation of Immuno- flourescence antibody (IFA) and Immuno-peroxidase Test (IPT) among 200 pregnant women for toxoplasmosis. Med J Mashhad Univ Med Sci. 2001; 44: 16-21.

Sarkari B, Shafiei R, Zare M, Sohrabpour S, Kasraian L. Seroprevalence and molecular diagnosis of Toxoplasma gondii infection among blood donors in southern Iran. J Infect Dev Ctries. 2014; 8(4): 543-7.

Boronow J, Dickerson F, Stallings C, Lee B, Origoni A, Yolken R. HSV-1. CMV and Toxoplasma serology predict cognitive deficits in schizophrenia. Schizophr Res. 2002; 53: 85.

Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(1): 4-8.

Nascimento FS, de Rosalmeida Dantas C, Netto MP et al. Prevalence of antibodies to Toxoplasma gondii in patients with schizophrenia and mood disorders. Schizophr Res. 2012; 142(1-3): 244-5.

Qiuying L, Xiaonian L. Li L. The control study of schizophrenia and affective disorders and Toxoplasma infections. Acta Academiae Medicinae Hubei. 1999; 20: 223-5.

Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003; 9(11): 1375-80.

Cetinkaya Z, Yazar S, Gecici O, Namli MN. Anti-Toxoplasma gondii antibodies in patients with schizophrenia--preliminary findings in a Turkish sample. Schizophr Bull. 2007; 33(3): 789-91.

Gu H, Yolken RH, Phillips M, Yange F, Bilder RM, Gilmore JH. Evidence of Toxoplasma gondii infection in recent-onset schizophrenia. Schizophr Res. 2001; 49: 53.

Yolken RH, Bachmann S, Ruslanova I et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001; 32(5): 842-4.

Alipour A, Shojaee S, Mohebali M, Tehranidoost M, Abdi Masoleh F, Keshavarz H. Toxoplasma infection in schizophrenia patients: a comparative study with control group. Iran J Parasitol. 2011; 6(2):31-7

Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003; 62(3): 237-44.

Published
2017-02-27
How to Cite
1.
ABDOLLAHIAN E, SHAFIEI R, MOKHBER N, KALANTAR K, FATA A. Seroepidemiological Study of Toxoplasma gondii Infection among Psychiatric Patients in Mashhad, Northeast of Iran. Iran J Parasitol. 12(1):117-122.
Section
Original Article(s)